ClinicalTrials.gg
CompletedNCT06488209Updated Nov 24, 2025

Single and Multiple Ascending Dose Study in Healthy Participants and Participants With an Autoimmune Disease

A Phase 1 interventional study of LAD191 and Placebo in Healthy Volunteers and Autoimmune Disease, sponsored by Almirall, S.A.. Completed at 3 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-24.

Sponsored by Almirall, S.A. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2025, 1 year 7 months ago, and no results have been posted to the registry.
  • Registered 1 year 10 months after the study started (first participant enrolled Jul 2022, registered Jun 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 341 studies in Autoimmune Diseases with a site in United States — 91 open to participants now, 117 under way, 19 of them phase 3. Autoimmune Diseases · United States.

Enrollment
106th of 243
69 · median 53
Started
2022
with 14 others
Phase 1
62 of 341
16 open now
Registered
298th of 341
by date

Among the 341 studies in Autoimmune Diseases with a site in United States, this one is the 106th largest by enrollment of the 243 interventional ones that give a count, is one of 15 that started in 2022, is one of 62 in phase 1, and was the 298th registered.

Autoimmune Diseases

803 studies on the registry are indexed under Autoimmune Diseases; 272 are open to participants now.

Browse Autoimmune Diseases studies →

Open to participants now

91 of the 341 studies in Autoimmune Diseases with a site in United States are open now. Recruiting first, the newest first:

86 more — sign in →

All 91 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 195 Autoimmune Diseases studies recruiting now, 90 (46%) set no upper age limit and 79 (41%) stop at 75 or younger; 55 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 341 studies in Autoimmune Diseases with a site in United States, or all of them as a file.
02

Study summary

The main purpose of this study is to to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity of LAD191 in healthy adults and in adults with an autoimmune disease.

Read the detailed description

This is a 3-part study. Part 1 will be comprised of up to 5 cohorts of healthy adult participants and will investigate single ascending doses of LAD191. Part 2 will be comprised of up to 3 cohorts of healthy adult participants and will investigate multiple ascending doses of LAD191. Part 3 will be comprised of single cohort of participants with an autoimmune disease and will investigate repeat doses of LAD191. Each ascending dose level will be investigated by a sequential cohort, with dose escalation based on satisfactory safety, tolerability, PK, PD, immunogenicity, biomarker and clinical response assessments will be performed throughout.

Each cohort will be randomized to receive LAD191 and placebo.

Each participant will participate for about 14 weeks in Part 1, 17 weeks in Part 2 and 18 weeks in Part 3 of the study.

03

Conditions studied

  • Healthy Volunteers
  • Autoimmune Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

(Applicable to Both Healthy and an Disease Participants Unless Indicated Otherwise)

  1. Participant provides written prior to any protocol related procedures, including screening evaluations. Participant must be able to understand the consent form and instructions and to provide consent directly; no guardian/legal representative or caregiver may provide consent for the participant.
  2. Male or female, greater than or equal to (>=)18 and less than or equal to (\<=) 65 years of age, with a (BMI) within the range of 18.5 to 29.9 kilogram per square meter (kg/m\^2) (inclusive) and body weight of >=50 kilograms (kg).
  3. Participant is healthy, in the clinical judgement of the Investigator, based medical history, physical examination, vital signs, , and laboratory investigations (i.e., has clinical laboratory tests that are within the reference ranges or are clinically acceptable per Investigator judgment).
  4. Participant has a seated systolic blood pressure (SBP) >=90 mm Hg and \<=140 mm Hg or a seated diastolic BP (DBP) >=50 mm Hg or \<=90 mm Hg.
  5. Participant is willing and able to understand and comply with all aspects of the protocol.
  6. Participant must agree to the following requirements during the study:

    • Women of (WOCBP) must have a negative serum pregnancy test result within 7 days prior to first dosing plus a negative urine pregnancy test pre-dose on Day 1 and must be willing to use a highly effective form of (ICH E8 Guideline, 1997; (ICH M3 [R2] Guidance, 2009; (FDA M3 [R2] Guidance, 2010) for the duration of the study and for at least 3 months after the last dose of study medication. Methods like periodic abstinence, post-ovulation procedures and withdrawal are not considered adequate.
    • Males with partners of childbearing potential must be willing to use condoms in combination with a second effective method of contraception during the study. Male participants must continue to use contraception (condoms plus a second effective method) for 165 days following administration of the study drug.
    • Male participants must agree not to donate sperm during the study and for 165 days following administration of the study drug.

Participants with an Autoimmune Disease (Cohort 9 Only):

For participants with an autoimmune disease, the inclusion criteria for healthy participants listed above apply, with the following changes/additions:

  1. Male or female, >=18 to \<=65 years of age, with a BMI within the range 18.5 to 34.9 kg/ m\^2, and body weight of >=50 kg.
  2. Current diagnosis of an autoimmune disease by the Investigator and with signs and symptoms consistent with an autoimmune disease for at least 3 months prior to Day -1 (baseline).

Exclusion criteria

Exclusion Criteria:

(Applicable to Both Healthy and an Disease Participants Unless Indicated Otherwise)

  1. Participant has received treatment with LAD191 previously.
  2. Known to LAD191 or any of its .
  3. Hypersensitivity or reaction to a prior biologic (antibody-based) therapy (regardless of indication), that was , as per judgment of Investigator.
  4. History of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, inflammatory, or allergic disease (including drug allergies, any active seizure disorder requiring therapy with antiepileptic drugs, active peptic ulcer disease, gastrointestinal bleeding, chronic gastritis, inflammatory bowel disease or chronic diarrhea, but excluding mild seasonal allergies or stable, well-controlled thyroiditis). Note that participants with thyroid hormone deficiency, hypertension, hyperlipidemia, or diabetes mellitus may be included in Part 3 of the study.
  5. Active chronic or acute infection requiring treatment with systemic antimicrobials, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before Day -1, or superficial skin infections within 4 weeks prior to Day -1, or fever > 38°C during within 1 week before Day -1.
  6. A positive test for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) on Day -1, or the second negative test after a previous SARS CoV-2 infection was \<=14 days before Day -1, or the participant's SARS CoV-2-associated symptoms resolved \<=14 days before Day -1.
  7. Presence of skin comorbidities that may interfere with study assessments, in the opinion of the Investigator.
  8. Participant has current tuberculosis (TB) or any history of active or latent TB, regardless of prior treatment.
  9. History of , regardless of outcome.
  10. Participant has any condition that, in the opinion of the Investigator, would interfere with the PK evaluation of LAD191 or participant safety or the interpretation of study results
  11. Clinically significant abnormality, including, but not limited to, the following:

    • An abnormal PR interval (>=220 msec or \<=100 msec).
    • prolongation (corrected QT interval by Fredericia's formula [QTcF] >=450 msec).
    • Mean heart rate \<=45 bpm or >100 bpm.
  12. Known history of liver disease or clinically significant abnormal (as per judgment of Investigator) liver function test(s) at Screening (, AST, alkaline phosphatase [ALP], or TBili >1.5 x ).
  13. Impaired renal function (laboratory values out of the normal range that are clinically significant, as judged by the Investigator).
  14. Congenital or acquired condition that would put participant at risk during the study, per Investigator judgment.
  15. Neutropenia; defined as a \<2.0 x 10\^9/L, at Screening.
  16. Participant has had major surgery (requiring general anesthesia) within 3 months prior to Day -1, or has major surgery planned during the study. For participants with an autoimmune disease may have had incision and drainage of abscesses up to 1 week before Day -1).
  17. Participant has donated plasma or blood or has lost more than 450 ml blood in the 60 days prior to Day -1, or intends to donate blood during the study or in the 60 days after the last scheduled study visit.
  18. Participant is pregnant or breastfeeding (or is planning to become pregnant or breastfeed during the study or within 90 days after the last dose of study drug).
  19. History of, or positive test result at Screening for, surface antigen (HBsAg), antibody to hepatitis B core antigen (anti-HBcAg), antibody to the virus (anti-HCV), or antibody to the (HIV-1/2).
  20. Participant has taken any medications, including over-the-counter (OTC) medications, within 14 days (or at least 5 half-lives, whichever is longer) before Day -1. (Note that hormonal are allowed, and acetaminophen is permitted at doses \<=2 g/day up to 48 hours prior to each study visit).
  21. Participant has received any type of live or attenuated vaccinations within 28 days prior to Screening, or is planning to receive any such vaccine during the study (inactive vaccines are allowed) or has received a SARS-CoV-2 vaccine within 14 days of Day 1.
  22. Participant has received any drug in any clinical study within 30 days (or at least 5 half-lives, whichever is longer) prior to Day -1, or is on extended follow-up from such a clinical study.
  23. Participant has a history (within 2 years prior to Screening) of alcohol or drug abuse, as per Investigator judgment, or has a positive urine screen for drugs of abuse (opiates, cocaine, amphetamines, cannabinoids, barbiturates, benzodiazepines, cotinine, phencyclidine) at Screening or on Day -1, or a positive urine alcohol test at Screening or on Day -1.
  24. Consumption of alcohol within 48 hours (2 days) before Day -1.
  25. Participant is involved in strenuous physical activity or contact sports within 96 hours (4 days) prior to Day -1.
  26. Consumption of any foods containing poppy seeds within 48 hours (2 days) prior to Screening and Day -1 as this could result in a false positive drug screen result.
  27. Participant has any other serious or uncontrolled physical or mental dysfunction that, as judged by the Investigator, could place the participant at higher risk derived from his/her participation in the trial, could confound the results of the trial or is likely to prevent the participant from complying with the requirements of the trial or completing the trial.
  28. Participant is an employee or relative of the Sponsor/vendors, clinical study site, or is an individual or employee directly involved with the conduct of the study or is an immediate family member of such an individual.

Participants with an Autoimmune Disease (Cohort 9 Only)

For participants with an autoimmune disease, the exclusion criteria for healthy participants listed above apply, with the following additions:

1. Concurrent use of the following medications/treatments:

  • Systemic immunosuppressants/immunomodulators or other systemic treatments for autoimmune disease within 28 days or 5 half-lives (whichever is longer) before Day -1.
  • Systemic antivirals or antifungals within 28 days prior to Day -1, or systemic antibiotics within 28 days prior to Day -1.
  • Oral analgesics including opioids within 14 days prior to Day -1, except for acetaminophen at doses of \<=2 g/day for relief of autoimmune disease-associated pain.
  • Prescription and OTC medications other than those used for the treatment of an autoimmune disease within 14 days or 5 half-lives (whichever is longer) before Day -1, except for hormonal contraceptives, thyroid replacement medications, and medications used for the treatment of hypertension, diabetes mellitus (but not metformin), or hyperlipidemia which are permitted provided the medication(s) and dosage (dose and frequency) have been stable for at least 6 weeks prior to Day -1. Note that participants with thyroid hormone deficiency, hypertension, diabetes mellitus, or hyperlipidemia may be included in Part 3 of the study.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Care provider)
Enrollment
69 participants (actual)

Study arms

  • Experimental
    Part 1: LAD191 (Cohort 1)

    Participants will receive single ascending dose of LAD191 subcutaneous (SC) injection on Day 1.

    Drug: LAD191

  • Experimental
    Part 1: LAD191 (Cohort 2)

    Participants will receive single ascending dose of LAD191 SC injection on Day 1.

    Drug: LAD191

  • Experimental
    Part 1: LAD191 (Cohort 3)

    Participants will receive single ascending dose of LAD191 SC injection on Day 1.

    Drug: LAD191

  • Experimental
    Part 1: LAD191 (Cohort 4)

    Participants will receive single ascending dose of LAD191 SC injection on Day 1.

    Drug: LAD191

  • Experimental
    Part 1: LAD191 (Cohort 5)

    Participants will receive single ascending dose of LAD191 SC injection on Day 1.

    Drug: LAD191

  • Placebo comparator
    Part 1: Placebo

    Participants will receive single dose of matching placebo SC injection on Day 1 (Cohort 1 to Cohort 5).

    Other: Placebo

  • Experimental
    Part 2: LAD191 (Cohort 6)

    Participants will receive multiple ascending doses of LAD191 SC injection on Days 1, 8, 15, 22, 29 and 36.

    Drug: LAD191

  • Experimental
    Part 2: LAD191 (Cohort 7)

    Participants will receive multiple ascending doses of LAD191 SC injection on Days 1, 8, 15, 22, 29 and 36.

    Drug: LAD191

  • Experimental
    Part 2: LAD191 (Cohort 8)

    Participants will receive multiple ascending doses of LAD191 SC injection on Days 1, 8, 15, 22, 29 and 36.

    Drug: LAD191

  • Placebo comparator
    Part 2: Placebo

    Participants will receive multiple doses of matching placebo SC injection on Days 1, 8, 15, 22, 29 and 36 (Cohort 6 to Cohort 8).

    Other: Placebo

  • Experimental
    Part 3: LAD191 (Cohort 9)

    Participants will receive repeat doses of LAD191 SC injection on Days 1, 8, 15, 22, 29 and 36.

    Drug: LAD191

  • Placebo comparator
    Part 3: Placebo

    Participants will receive repeat doses of matching placebo SC injection on Days 1, 8, 15, 22, 29 and 36 (Cohort 9).

    Other: Placebo

Interventions

  • DrugLAD191

    LAD191 SC injection.

  • OtherPlacebo

    Matching placebo SC injection.

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants with Adverse Events (AEs) and Severity of AEs

    Time frame: Baseline up to Day 73

  2. Part 1: Number of Participants who have Dose-limiting Adverse Reactions

    Time frame: Baseline up to Day 73

  3. Part 1: Number of Participants with Clinically Significant Changes from Baseline in Vital Sign Parameter

    Time frame: Baseline up to Day 73

  4. Part 1: Number of Participants with Clinically Significant Changes from Baseline in Physical Examination Findings

    Time frame: Baseline up to Day 73

  5. Part 1: Number of Participants with Clinically Significant Changes from Baseline in Electrocardiograms (ECGs) Parameters

    Time frame: Baseline up to Day 73

  6. Part 1: Number of Participants with Clinically Significant Changes from Baseline in Clinical Laboratory Parameters

    Time frame: Baseline up to Day 73

  7. Part 2 and 3: Number of Participants with Adverse Events (AEs) and Severity of AEs

    Time frame: Baseline up to Day 94

  8. Part 2 and 3: Number of Participants who have Dose-limiting Adverse Reactions

    Time frame: Baseline up to Day 94

  9. Part 2 and 3: Number of Participants with Clinically Significant Changes from Baseline in Vital Sign Parameter

    Time frame: Baseline up to Day 94

  10. Part 2 and 3: Number of Participants with Clinically Significant Changes from Baseline in Physical Examination Findings

    Time frame: Baseline up to Day 94

  11. Part 2 and 3: Number of Participants with Clinically Significant Changes from Baseline in ECGs Parameters

    Time frame: Baseline up to Day 94

  12. Part 2 and 3: Number of Participants with Clinically Significant Changes from Baseline in Clinical Laboratory Parameters

    Time frame: Baseline up to Day 94

Secondary outcomes

  1. Part 1: Maximum Serum Concentration (Cmax) of LAD191

    Time frame: Pre-dose, 4 hours and 8 hours post-dose on Days 1, 2, 3, 4, 6, 8, 15, 22, 29, 43, 57 and 71

  2. Part 1: Time to Reach Maximum Serum Concentration (Tmax) of LAD191

    Time frame: Pre-dose, 4 hours and 8 hours post-dose on Days 1, 2, 3, 4, 6, 8, 15, 22, 29, 43, 57 and 71

  3. Part 1: Area Under the Serum Concentration-time Curve from Zero to Time of the Last Quantifiable Concentration (AUC0-t) of LAD191

    Time frame: Pre-dose, 4 hours and 8 hours post-dose on Days 1, 2, 3, 4, 6, 8, 15, 22, 29, 43, 57 and 71

  4. Part 1: Area Under the Serum Concentration-time Curve from Zero to infinity (AUC0-inf) of LAD191

    Time frame: Pre-dose, 4 hours and 8 hours post-dose on Days 1, 2, 3, 4, 6, 8, 15, 22, 29, 43, 57 and 71

  5. Part 1: Elimination Half-life (t½) of LAD191

    Time frame: Pre-dose, 4 hours and 8 hours post-dose on Days 1, 2, 3, 4, 6, 8, 15, 22, 29, 43, 57 and 71

  6. Part 1: Apparent Total Serum Clearance (CL/F) of LAD191

    Time frame: Pre-dose, 4 hours and 8 hours post-dose on Days 1, 2, 3, 4, 6, 8, 15, 22, 29, 43, 57 and 71

  7. Part 1: Apparent Volume of Distribution Associated with the Terminal Phase (Vd/F) of LAD191

    Time frame: Pre-dose, 4 hours and 8 hours post-dose on Days 1, 2, 3, 4, 6, 8, 15, 22, 29, 43, 57 and 71

  8. Part 1: Number of Participants with Positive Anti-drug Antibodies (ADA) and Titer of ADA of LAD191

    Time frame: Pre-dose on Day 1; 24 hours post-dose on Days 15; 48 hours post-dose on Days 43 and 71

  9. Part 2: Area Under the Serum Concentration-time Curve from Zero to Time of the Last Quantifiable Concentration (AUC0-t) of LAD191

    Time frame: Pre-dose at Days 1, 8, 15, 22, 29, and 36; At 4 hours, 24 hours and 48 hours post-dose on Days 1, 36, 40, 43, 50, 64, 85 and 92

  10. Part 2: Area Under the Concentration-time Curve within a Dosing Interval (AUCτau) of LAD191

    Time frame: Pre-dose at Days 1, 8, 15, 22, 29, and 36; At 4 hours, 24 hours and 48 hours post-dose on Days 1, 36, 40, 43, 50, 64, 85 and 92

  11. Part 2: Maximum Serum Concentration (Cmax) of LAD191

    Time frame: Pre-dose at Days 1, 8, 15, 22, 29, and 36; At 4 hours, 24 hours and 48 hours post-dose on Days 1, 36, 40, 43, 50, 64, 85 and 92

  12. Part 2: Time to Reach Maximum Serum Concentration (Tmax) of LAD191

    Time frame: Pre-dose at Days 1, 8, 15, 22, 29, and 36; At 4 hours, 24 hours and 48 hours post-dose on Days 1, 36, 40, 43, 50, 64, 85 and 92

  13. Part 2: Minimum Serum Concentrations (Cmin) of LAD191

    Time frame: Pre-dose at Days 1, 8, 15, 22, 29, and 36; At 4 hours, 24 hours and 48 hours post-dose on Days 1, 36, 40, 43, 50, 64, 85 and 92

  14. Part 2: Time to Cmin (tmin) of LAD191

    Time frame: Pre-dose at Days 1, 8, 15, 22, 29, and 36; At 4 hours, 24 hours and 48 hours post-dose on Days 1, 36, 40, 43, 50, 64, 85 and 92

  15. Part 2: Area Under the Serum Concentration-time Curve from Zero to Time of the Last Quantifiable Concentration (AUC0-t) at Steady State of LAD191

    Time frame: Pre-dose at Days 1, 8, 15, 22, 29, and 36; At 4 hours, 24 hours and 48 hours post-dose on Days 1, 36, 40, 43, 50, 64, 85 and 92

  16. Part 2: Area Under the Concentration-time Curve within a Dosing Interval (AUCτau) at Steady State of LAD191

    Time frame: Pre-dose at Days 1, 8, 15, 22, 29, and 36; At 4 hours, 24 hours and 48 hours post-dose on Days 1, 36, 40, 43, 50, 64, 85 and 92

  17. Part 2: Maximum Serum Concentration (Cmax) at Steady State of LAD191

    Time frame: Pre-dose at Days 1, 8, 15, 22, 29, and 36; At 4 hours, 24 hours and 48 hours post-dose on Days 1, 36, 40, 43, 50, 64, 85 and 92

  18. Part 2: Time to Reach Maximum Serum Concentration (Tmax) at Steady State of LAD191

    Time frame: Pre-dose at Days 1, 8, 15, 22, 29, and 36; At 4 hours, 24 hours and 48 hours post-dose on Days 1, 36, 40, 43, 50, 64, 85 and 92

  19. Part 2: Minimum Serum Concentrations (Cmin) at Steady State of LAD191

    Time frame: Pre-dose at Days 1, 8, 15, 22, 29, and 36; At 4 hours, 24 hours and 48 hours post-dose on Days 1, 36, 40, 43, 50, 64, 85 and 92

  20. Part 2: Time to Cmin (tmin) at Steady State of LAD191

    Time frame: Pre-dose at Days 1, 8, 15, 22, 29, and 36; At 4 hours, 24 hours and 48 hours post-dose on Days 1, 36, 40, 43, 50, 64, 85 and 92

  21. Part 2: Apparent Total Serum Clearance (CL/F) of LAD191

    Time frame: Pre-dose at Days 1, 8, 15, 22, 29, and 36; At 4 hours, 24 hours and 48 hours post-dose on Days 1, 36, 40, 43, 50, 64, 85 and 92

  22. Part 2: Apparent Volume of Distribution Associated with the Terminal Phase (Vd/F) of LAD191

    Time frame: Pre-dose at Days 1, 8, 15, 22, 29, and 36; At 4 hours, 24 hours and 48 hours post-dose on Days 1, 36, 40, 43, 50, 64, 85 and 92

  23. Part 2: Elimination Half-life (t½) of LAD191

    Time frame: Pre-dose at Days 1, 8, 15, 22, 29, and 36; At 4 hours, 24 hours and 48 hours post-dose on Days 1, 36, 40, 43, 50, 64, 85 and 92

  24. Part 2: Accumulation Ratios Based on AUC (R[AUC]) of LAD191

    Time frame: Pre-dose at Days 1, 8, 15, 22, 29, and 36; At 4 hours, 24 hours and 48 hours post-dose on Days 1, 36, 40, 43, 50, 64, 85 and 92

  25. Part 2 and 3: Number of Participants with Positive ADA and Titer of ADA of LAD191

    Time frame: Pre-dose on Days 1, 15, and 29; 4 hours post-dose on Days 43; 48 hours post-dose on 64 and 92

  26. Part 3: Area Under the Serum Concentration-time Curve from Zero to Time of the Last Quantifiable Concentration (AUC0-t) of LAD191

    Time frame: Pre-dose at Days 1, 8, 15, 22, 29, and 36; At 4 hours and 48 hours post-dose on Days 1, 36, 40, 43, 50, 64, 85 and 92

  27. Part 3: Area Under the Concentration-time Curve within a Dosing Interval (AUCτau) of LAD191

    Time frame: Pre-dose at Days 1, 8, 15, 22, 29, and 36; At 4 hours and 48 hours post-dose on Days 1, 36, 40, 43, 50, 64, 85 and 92

  28. Part 3: Maximum Serum Concentration (Cmax) of LAD191

    Time frame: Pre-dose at Days 1, 8, 15, 22, 29, and 36; At 4 hours and 48 hours post-dose on Days 1, 36, 40, 43, 50, 64, 85 and 92

  29. Part 3: Time to Reach Maximum Serum Concentration (Tmax) of LAD191

    Time frame: Pre-dose at Days 1, 8, 15, 22, 29, and 36; At 4 hours and 48 hours post-dose on Days 1, 36, 40, 43, 50, 64, 85 and 92

  30. Part 3: Minimum Serum Concentrations (Cmin) of LAD191

    Time frame: Pre-dose at Days 1, 8, 15, 22, 29, and 36; At 4 hours and 48 hours post-dose on Days 1, 36, 40, 43, 50, 64, 85 and 92

  31. Part 3: Time to Cmin (tmin) of LAD191

    Time frame: Pre-dose at Days 1, 8, 15, 22, 29, and 36; At 4 hours and 48 hours post-dose on Days 1, 36, 40, 43, 50, 64, 85 and 92

  32. Part 3: Area Under the Serum Concentration-time Curve from Zero to Time of the Last Quantifiable Concentration (AUC0-t) at Steady State of LAD191

    Time frame: Pre-dose at Days 1, 8, 15, 22, 29, and 36; At 4 hours and 48 hours post-dose on Days 1, 36, 40, 43, 50, 64, 85 and 92

  33. Part 3: Area Under the Concentration-time Curve within a Dosing Interval (AUCτau) at Steady State of LAD191

    Time frame: Pre-dose at Days 1, 8, 15, 22, 29, and 36; At 4 hours and 48 hours post-dose on Days 1, 36, 40, 43, 50, 64, 85 and 92

  34. Part 3: Maximum Serum Concentration (Cmax) at Steady State of LAD191

    Time frame: Pre-dose at Days 1, 8, 15, 22, 29, and 36; At 4 hours and 48 hours post-dose on Days 1, 36, 40, 43, 50, 64, 85 and 92

  35. Part 3: Time to Reach Maximum Serum Concentration (Tmax) at Steady State of LAD191

    Time frame: Pre-dose at Days 1, 8, 15, 22, 29, and 36; At 4 hours and 48 hours post-dose on Days 1, 36, 40, 43, 50, 64, 85 and 92

  36. Part 3: Minimum Serum Concentrations (Cmin) at Steady State of LAD191

    Time frame: Pre-dose at Days 1, 8, 15, 22, 29, and 36; At 4 hours and 48 hours post-dose on Days 1, 36, 40, 43, 50, 64, 85 and 92

  37. Part 3: Time to Cmin (tmin) at Steady State of LAD191

    Time frame: Pre-dose at Days 1, 8, 15, 22, 29, and 36; At 4 hours and 48 hours post-dose on Days 1, 36, 40, 43, 50, 64, 85 and 92

  38. Part 3: Apparent Total Serum Clearance (CL/F) of LAD191

    Time frame: Pre-dose at Days 1, 8, 15, 22, 29, and 36; At 4 hours and 48 hours post-dose on Days 1, 36, 40, 43, 50, 64, 85 and 92

  39. Part 3: Apparent Volume of Distribution Associated with the Terminal Phase (Vd/F) of LAD191

    Time frame: Pre-dose at Days 1, 8, 15, 22, 29, and 36; At 4 hours and 48 hours post-dose on Days 1, 36, 40, 43, 50, 64, 85 and 92

  40. Part 3: Elimination Half-life (t½) of LAD191

    Time frame: Pre-dose at Days 1, 8, 15, 22, 29, and 36; At 4 hours and 48 hours post-dose on Days 1, 36, 40, 43, 50, 64, 85 and 92

  41. Part 3: Accumulation Ratios Based on AUC (R[AUC]) of LAD191

    Time frame: Pre-dose at Days 1, 8, 15, 22, 29, and 36; At 4 hours and 48 hours post-dose on Days 1, 36, 40, 43, 50, 64, 85 and 92

07

Study locations

3 sites
  • Doral Medical Research
    Miami, Florida 33165, United States
  • Jennifer Parish, MD
    Philadelphia, Pennsylvania 19103, United States
  • ICON Early Phase Services, LLC
    San Antonio, Texas 78209, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Apr 2025, 32 months.

Of 69 industry-sponsored phase 1 interventional studies under Autoimmune Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 32. This study's 32 months is above that.

Counting every sponsor, half of 95 studies reached it within 23 months; a quarter within 9 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2024
First posted
Jul 5, 2024
StartActual
Jul 29, 2022
Primary completionActual
Apr 3, 2025
CompletionActual
Apr 3, 2025
Last update
Nov 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06488209
Lead sponsor
Almirall, S.A.
Responsible party
Sponsor
First posted
Jul 5, 2024
Start date
Jul 29, 2022
Primary completion
Apr 3, 2025
Completion
Apr 3, 2025
Last update
Nov 24, 2025

Study contacts

Study Director
study director · Almirall, S.A.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion